Kathryn E. Falberg - 21 May 2026 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Reporting relationship: Director
Issuer ticker: NUVB
Reported as of: 21 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2026, 20:05:50 UTC
Prior SEC filing: 25 Mar 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Dang, Attorney-in-Fact

Key filing fact

Kathryn E. Falberg filed Form 4 for Nuvation Bio Inc. (NUVB) on 26 May 2026.

Key facts

This page summarizes Kathryn E. Falberg's Form 4 filing for Nuvation Bio Inc. (NUVB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 May 2026, 20:05.

Change

Previous filing in this sequence was filed on 25 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001206977 Primary reporting owner

FALBERG KATHRYN E

Relationship: Director
Address: C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK
Signature: /s/ Stephen Dang, Attorney-in-Fact
Signature date: 26 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +123,397
Change %
Price: $0.000000^*
Shares after: 123,397
Date: 21 May 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 123,397
Exercise price: $4.79
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.